Valeant Pharmaceuticals Intl (NYSE:VRX) EVP Laizer Kornwasser acquired 2,481 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Friday, March 21st. The stock was purchased at an average price of $134.97 per share, with a total value of $334,860.57. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares after opening at $132.26 moved to $133.47 on last trade day and at the end of the day closed at $129.07 . Company price to sales ratio in past twelve months was calculated as 7.49 and price to cash ratio as 71.94. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) showed a negative weekly performance of -8.32 %.
PetMed Express, Inc (NASDAQ:PETS) experiences a ratings drop this week, going from last week’s C to a D. PetMed Express offers prescription and nonprecription pet medications, as well as health and nutritional supplements. As of March 24, 2014, 15.7% of outstanding PetMed Express, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of PETS stock. Petmed Express Inc (NASDAQ:PETS) shares fell -0.15% in last trading session and ended the day on $13.14. PETS return on equity ratio is recorded as 34.30 % and its return on assets is 29.70%. Petmed Express Inc (NASDAQ:PETS) yearly performance is 1.94%.
Alkermes Plc (NASDAQ:ALKS) CFO James Frates unloaded 7,000 shares of the stock on the open market in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $46.84, for a total transaction of $327,880.00. Alkermes Plc (NASDAQ:ALKS) shares moved down -1.03% in last trading session and was closed at $43.26 while trading in range of $43.25 – $45.00 – Alkermes Plc (NASDAQ:ALKS) year to date (YTD) performance is 6.39%.
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States. Notice of Allowance is the final step in the issuance of a patent. The company believes that this patent will significantly strengthen Adamis’ cancer immunotherapy patent portfolio and will further support its TeloB-VAX vaccine technology. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) weekly performance is -5.22%. On last trading day company shares ended up $6.35. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) distance from 50-day simple moving average (SMA50) is -2.43%. Analysts mean target price for the company is $15.00.